乳腺癌诊疗指南(2022年版)

2022-04-11 中华人民共和国国家卫生健康委员会 中华人民共和国国家卫生健康委员会官网

为进一步规范我国乳腺癌诊疗行为,提高医疗机构乳腺癌诊疗水平,改善乳腺癌患者预后,保障医疗质量和医疗安全,特制定本指南。

中文标题:

乳腺癌诊疗指南(2022年版)

发布日期:

2022-04-11

简要介绍:

乳腺癌是女性常见的恶性肿瘤之一,发病率位居女性恶性肿瘤的首位,严重危害妇女的身心健康。目前,通过采用综合治疗手段,乳腺癌已成为疗效最佳的实体肿瘤之一。为进一步规范我国乳腺癌诊疗行为,提高医疗机构乳腺癌诊疗水平,改善乳腺癌患者预后,保障医疗质量和医疗安全,特制定本指南。

相关资料下载:
[AttachmentFileName(sort=1, fileName=乳腺癌诊疗指南+(2022年版).pdf)] GetToolGuiderByIdResponse(projectId=1, id=2d53a1c00250989b, title=乳腺癌诊疗指南(2022年版), enTitle=, guiderFrom=中华人民共和国国家卫生健康委员会官网, authorId=0, author=, summary=为进一步规范我国乳腺癌诊疗行为,提高医疗机构乳腺癌诊疗水平,改善乳腺癌患者预后,保障医疗质量和医疗安全,特制定本指南。, cover=https://img.medsci.cn/Random/diagnostic-form-in-hospital-conceptual-image-7JAH3GT.jpg, journalId=0, articlesId=null, associationId=1653, associationName=中华人民共和国国家卫生健康委员会, associationIntro=, copyright=0, guiderPublishedTime=Mon Apr 11 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">乳腺癌是女性常见的恶性肿瘤之一,发病率位居女性恶性肿瘤的首位,严重危害妇女的身心健康。目前,通过采用综合治疗手段,乳腺癌已成为疗效最佳的实体肿瘤之一。为进一步规范我国乳腺癌诊疗行为,提高医疗机构乳腺癌诊疗水平,改善乳腺癌患者预后,保障医疗质量和医疗安全,特制定本指南。</span></p>, tagList=[TagDto(tagId=72213, tagName=国家卫健委), TagDto(tagId=440210, tagName=乳腺癌诊疗指南)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=89, categoryName=乳腺癌, tenant=100), CategoryDto(categoryId=21054, categoryName=梅斯医学-乳腺癌网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=285, articleKeyword=乳腺癌, articleKeywordNum=6, guiderKeywordId=308, guiderKeyword=诊疗指南, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=19366, appHits=694, showAppHits=0, pcHits=2622, showPcHits=18671, likes=0, shares=95, comments=4, approvalStatus=1, publishedTime=Tue Jul 12 20:35:00 CST 2022, publishedTimeString=2022-04-11, pcVisible=1, appVisible=1, editorId=0, editor=lixiang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=7, createdBy=null, createdName=lixiang, createdTime=Thu Jul 07 17:06:42 CST 2022, updatedBy=6459136, updatedName=艺玮, updatedTime=Sat Jan 06 18:43:22 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=乳腺癌诊疗指南+(2022年版).pdf)])
乳腺癌诊疗指南+(2022年版).pdf
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2226357, encodeId=0571222635e23, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=655b8245725, createdName=ms6000000190242997, createdTime=Wed Sep 18 11:06:35 CST 2024, time=2024-09-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1232906, encodeId=c7cb12329062d, content=好好学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Sun Jul 17 08:00:15 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232563, encodeId=94101232563f9, content=下载来学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220718/40f20a20ac39449bb9b54f0a56b3bd59/badab63a8f8940b1aa22f908b6cb9dc4.jpg, createdBy=5b9f6414712, createdName=ms5000000275821148, createdTime=Fri Jul 15 06:01:14 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232078, encodeId=d5f712320e86b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60445479842, createdName=ms2000000529313829, createdTime=Tue Jul 12 20:48:48 CST 2022, time=2022-07-12, status=1, ipAttribution=)]
    2024-09-18 ms6000000190242997 来自湖北省

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2226357, encodeId=0571222635e23, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=655b8245725, createdName=ms6000000190242997, createdTime=Wed Sep 18 11:06:35 CST 2024, time=2024-09-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1232906, encodeId=c7cb12329062d, content=好好学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Sun Jul 17 08:00:15 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232563, encodeId=94101232563f9, content=下载来学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220718/40f20a20ac39449bb9b54f0a56b3bd59/badab63a8f8940b1aa22f908b6cb9dc4.jpg, createdBy=5b9f6414712, createdName=ms5000000275821148, createdTime=Fri Jul 15 06:01:14 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232078, encodeId=d5f712320e86b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60445479842, createdName=ms2000000529313829, createdTime=Tue Jul 12 20:48:48 CST 2022, time=2022-07-12, status=1, ipAttribution=)]
    2022-07-17 海上飘星

    好好学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2226357, encodeId=0571222635e23, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=655b8245725, createdName=ms6000000190242997, createdTime=Wed Sep 18 11:06:35 CST 2024, time=2024-09-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1232906, encodeId=c7cb12329062d, content=好好学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Sun Jul 17 08:00:15 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232563, encodeId=94101232563f9, content=下载来学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220718/40f20a20ac39449bb9b54f0a56b3bd59/badab63a8f8940b1aa22f908b6cb9dc4.jpg, createdBy=5b9f6414712, createdName=ms5000000275821148, createdTime=Fri Jul 15 06:01:14 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232078, encodeId=d5f712320e86b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60445479842, createdName=ms2000000529313829, createdTime=Tue Jul 12 20:48:48 CST 2022, time=2022-07-12, status=1, ipAttribution=)]
    2022-07-15 ms5000000275821148

    下载来学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2226357, encodeId=0571222635e23, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=655b8245725, createdName=ms6000000190242997, createdTime=Wed Sep 18 11:06:35 CST 2024, time=2024-09-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1232906, encodeId=c7cb12329062d, content=好好学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Sun Jul 17 08:00:15 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232563, encodeId=94101232563f9, content=下载来学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220718/40f20a20ac39449bb9b54f0a56b3bd59/badab63a8f8940b1aa22f908b6cb9dc4.jpg, createdBy=5b9f6414712, createdName=ms5000000275821148, createdTime=Fri Jul 15 06:01:14 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232078, encodeId=d5f712320e86b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60445479842, createdName=ms2000000529313829, createdTime=Tue Jul 12 20:48:48 CST 2022, time=2022-07-12, status=1, ipAttribution=)]
    2022-07-12 ms2000000529313829

    学习

    0

拓展阅读

乳腺癌步入“慢病”时代,徐兵河院士详解乳腺癌防治要点

【医悦汇】特邀中国工程院徐兵河院士做客“科普ONCO”栏目,分享乳腺癌防治前沿观点。

【专家述评】|早期乳腺癌局部治疗与全身治疗的进展与展望

本文就早期乳腺癌局部和系统性治疗的现状、研究进展及展望予以综述,旨在为广大临床工作者提供参考。

【综述】|NRP-1靶向分子探针助力乳腺癌诊断的最新进展及展望

本文对NRP-1靶向分子探针在乳腺癌诊断中的优缺点进行系统比较,并阐述各类探针在乳腺癌诊疗领域的适用范围及最新研究进展,以期为乳腺癌靶向分子探针的研发及临床应用提供参考。

直击乳腺癌|热点资讯引领,课程、指南等全面赋能医疗人

此次,本文收集的乳腺癌热点资讯聚焦当下最热门话题,为你打开新视野。精心筹备的课程由业内资深人士倾囊相授,深入浅出地讲解乳腺癌相关知识。新近发布的指南更是含金量满满,是我们在临床工作中的得力助手。

Cancer Cell:乳腺癌中精氨酸-多胺-TDG通路如何“驯化”巨噬细胞,抑制T细胞抗癌能力

国际顶级期刊《Cancer Cell》(影响因子48.8)近日发表了一项颠覆性研究,首次揭示​

餐桌上的隐形推手?Science:新研究揭示ω-6脂肪酸亚油酸促进三阴性乳腺癌生长的机制

该研究定义了一种营养信号机制,涉及脂肪酸结合蛋白5 (FABP5)和雷帕霉素复合物1 (mTORC1)的机制靶点,它被必需的多不饱和脂肪酸(PUFA) ω-6亚油酸(LA)激活。

2022 BAD/BPG指南:窄谱中波紫外线光疗

英国皮肤科医师协会(BAD,British Association of Dermatologists) · 2022-05-23

2020 ECCO/ESPGHAN指南:儿童克罗恩病的药物治疗

欧洲克罗恩病和结肠炎组织(ECCO,European Cron&#039;s and Colitis Organisation) · 2020-10-07

中国乳腺癌筛查与早期诊断指南

中国抗癌协会乳腺癌专业委员会(CACA-CBCS,Chinese Anti-Cancer Association, Committee of Breast Cancer Society) · 2022-04-28

2020 AAO指南:成人眼科综合评估

美国眼科学会(AAO,American Academy of Ophthalmology) · 2020-11-30

疟疾诊疗指南

浙江大学医学院附属第一医院 · 2022-07-29

ESC和ACC/AHA/HFSA心力衰竭指南的建议之间的头对头比较

欧洲心脏病学会(ESC,European Society of Cardiology) · 2022-08-25